Brookline Capital Markets Estimates UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Several other brokerages have also recently issued reports on UNCY. Guggenheim dropped their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Westpark Capital began coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a “buy” rating on the stock. Benchmark dropped their price target on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Unicycive Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $25.67.

Unicycive Therapeutics Stock Down 3.4%

Shares of UNCY stock opened at $6.45 on Thursday. The stock has a market capitalization of $162.80 million, a PE ratio of -2.97 and a beta of 1.81. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The stock’s 50-day moving average price is $6.64 and its 200 day moving average price is $5.88.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. increased its position in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the period. Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics during the 4th quarter worth approximately $226,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth approximately $182,000. Finally, State Street Corp increased its position in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after purchasing an additional 10,400 shares during the period. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.